IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies

por Blauvelt, Andrew, Lebwohl, Mark G, Bissonnette, Robert
Publicado 2015

Spesolimab use in treatment of pyoderma gangrenosum

por Guénin, Sophie H., Khattri, Saakshi, Lebwohl, Mark G.
Publicado 2023

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review

por Blauvelt, Andrew, Chiricozzi, Andrea, Ehst, Benjamin D., Lebwohl, Mark G.
Publicado 2023

Cutaneous reaction reported after third Moderna COVID-19 vaccine

por Guénin, Sophie H., Kresch, Mindy, Elbogen, Emily, Lebwohl, Mark G.
Publicado 2021

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic...

por Lebwohl, Mark G., Kavanaugh, Arthur, Armstrong, April W., Van Voorhees, Abby S.
Publicado 2015

Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review

por Merola, Joseph F., Kavanaugh, Arthur, Lebwohl, Mark G., Gniadecki, Robert, Wu, Jashin J.
Publicado 2022

Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Charac...

por Lebwohl, Mark G., Papp, Kim A., Mørch, Marie Holst, Bernasconi, Marie Y. Jablonski, Warren, Richard B.
Publicado 2021

Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials

por Lebwohl, Mark G., Soliman, Ahmed M., Yang, Hongbo, Wang, Jessie, Hagan, Kaitlin, Padilla, Byron, Pinter, Andreas
Publicado 2021

Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity

por Vekaria, Anjali S., Brunner, Patrick M., Aleisa, Ahmad I., Bonomo, Lauren, Lebwohl, Mark G., Israel, Ariel, Guttman-Yassky, Emma
Publicado 2017

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits

por Lebwohl, Mark G., Tanghetti, Emil A., Stein Gold, Linda, Del Rosso, James Q., Gilyadov, Nelly K., Jacobson, Abby
Publicado 2021

COVID-19 Vaccine-Induced Lichenoid Eruptions—Clinical and Histopathologic Spectrum in a Case Series of Fifteen Patients with Review of the Literature

por Sapadin, Yonatan K., Mermelstein, Elazar, Phelps, Robert G., Basler, Christopher F., Tufariello, JoAnn M., Lebwohl, Mark G.
Publicado 2023

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

por Lebwohl, Mark G., Blauvelt, Andrew, Menter, Alan, Papp, Kim A., Guenthner, Scott, Pillai, Radhakrishnan, Israel, Robert J., Jacobson, Abby
Publicado 2019

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

por Geng, Bob, Hebert, Adelaide A., Takiya, Liza, Miller, Lauren, Werth, John L., Zang, Chuanbo, Sanders, Paul, Lebwohl, Mark G.
Publicado 2021

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

por Geng, Bob, Hebert, Adelaide A., Takiya, Liza, Miller, Lauren, Werth, John L., Zang, Chuanbo, Sanders, Paul, Lebwohl, Mark G.
Publicado 2021

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares

por Choon, Siew Eng, Lebwohl, Mark G, Turki, Hamida, Zheng, Min, Burden, A. David, Li, Ling, Quaresma, Manuel, Thoma, Christian, Bachelez, Hervé
Publicado 2023

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score

por Papp, Kim A., Lebwohl, Mark G., Kircik, Leon H., Pariser, David M., Strober, Bruce, Krueger, Gerald G., Berk, David R., Navale, Lynn, Higham, Robert C.
Publicado 2021

Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte–Associated Antigen 4–Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the...

por Abrams, Judith R., Kelley, Susan L., Hayes, Elizabeth, Kikuchi, Toyoko, Brown, Michael J., Kang, Sewon, Lebwohl, Mark G., Guzzo, Cynthia A., Jegasothy, Brian V., Linsley, Peter S., Krueger, James G.
Publicado 2000

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups

por Callender, Valerie D., Alexis, Andrew F., Stein Gold, Linda F., Lebwohl, Mark G., Paller, Amy S., Desai, Seemal R., Tan, Huaming, Ports, William C., Zielinski, Michael A., Tallman, Anna M.
Publicado 2019

Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis pre...

por Choon, Siew Eng, Lebwohl, Mark G, Marrakchi, Slaheddine, Burden, A David, Tsai, Tsen-Fang, Morita, Akimichi, Navarini, Alexander A, Zheng, Min, Xu, Jinhua, Turki, Hamida, Rajeswari, Sushmita, Deng, Hongjie, Tetzlaff, Kay, Thoma, Christian, Bachelez, Hervé
Publicado 2021

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

por Ungar, Benjamin, Glickman, Jacob W., Golant, Alexandra K., Dubin, Celina, Marushchak, Olga, Gontzes, Alyssa, Mikhaylov, Daniela, Singer, Giselle K., Baum, Danielle, Wei, Nancy, Sanin, Antonio, Gruenstein, Diana, Lebwohl, Mark G., Pavel, Ana B., Guttman-Yassky, Emma
Publicado 2022